India's dengue vaccine approval comes with critical safety gap for uninfected children

India's drug regulator has approved Qdenga, the country's first dengue vaccine, clearing it for use in children and adults aged 4 to 60 regardless of prior infection history. The vaccine is manufactured by Japan's Takeda Pharmaceutical and has already won approval in more than 40 countries. It was designed to protect against all four dengue virus serotypes—DENV-1, DENV-2, DENV-3, and DENV-4. But buried in the clinical trial data that Takeda published across 2019, 2020, and 2024 lies a troubling pattern that raises questions about whether the approval should have come with stricter conditions.

To understand the concern, you need to know how dengue immunity works. When someone gets infected with dengue for the first time, their body develops antibodies specific to whichever serotype they caught. If that same person later encounters a different serotype, those first antibodies can paradoxically make the second infection worse—a phenomenon called antibody-dependent enhancement, or ADE. This is why the ideal dengue vaccine must protect equally against all four serotypes. If it leaves someone vulnerable to even one, it creates a dangerous opening: they'll have antibodies from the vaccine that could amplify a natural infection, potentially triggering severe dengue.

Takeda's phase-3 trial enrolled roughly 20,000 healthy children aged 4 to 16 across eight countries in Latin America and Asia where dengue circulates widely. Two-thirds received Qdenga; one-third got a placebo. The headline numbers looked reassuring. In the vaccinated group, 5 children per 1,000 contracted dengue. In the unvaccinated group, 24 per 1,000 did. That's an 80 percent efficacy rate overall—solid on its face. When researchers separated participants by whether they'd been exposed to dengue before vaccination, efficacy was 82 percent in those with prior infection and 75 percent in those without.

But the granular breakdown by serotype tells a different story. In children who had never been infected with dengue before vaccination—the seronegative group—those who received Qdenga were 25 percent more likely to contract DENV-3 than unvaccinated children. The vaccine worked well against DENV-1 and DENV-2 regardless of prior exposure. Against DENV-4, there was almost no data; cases were so rare the efficacy remains essentially unknown. Takeda's researchers noted this pattern consistently across their publications, calling it "variable vaccine efficacy against the different serotypes" and a "numerical imbalance." The language was measured, but the implication was stark: Qdenga does not protect against DENV-3 in children never previously infected, and may actually increase their risk.

What happens next matters enormously. A seronegative child vaccinated with Qdenga receives what amounts to a simulated primary dengue infection—the vaccine is a live virus vaccine. Their immune system develops antibodies to DENV-1 and DENV-2. But they have no protection against DENV-3. If they later encounter DENV-3 in nature, it becomes a secondary infection in immunological terms. Those DENV-1 and DENV-2 antibodies from the vaccine can enhance the DENV-3 infection, potentially triggering severe dengue. The risk of DENV-4 infection in such children cannot even be predicted because efficacy data don't exist.

India has roughly 40 million children. Estimates suggest fewer than 30 percent have been exposed to dengue naturally. That means approximately 28 million seronegative children could face this heightened risk if vaccinated without prior screening. A research team from Imperial College London modeled the public health impact and concluded in a July 25 paper in Nature Medicine that seronegative recipients—particularly children—should be screened for prior dengue exposure before receiving the shot. The screening would identify who has already been infected and is therefore safe to vaccinate, and who remains vulnerable to the DENV-3 risk.

The approval of Qdenga without a mandatory screening requirement represents a gap between what the clinical data suggest and what the regulatory decision allows. The vaccine is not unsafe for everyone; it appears genuinely protective for those with prior dengue exposure and for DENV-1 and DENV-2 in general. But for a large population of Indian children with no prior infection history, the approval as currently framed could create a scenario where vaccination increases rather than decreases their risk of severe dengue. The solution is straightforward: screen before vaccinating. The question now is whether regulators will require it.